Strong association of high urinary iodine with thyroid nodule and papillary thyroid cancer

Fang Wang, Yangang Wang, Luan Wang, Xiuxiu Wang, Chun Sun, Michael Mingzhao Xing, Wenjuan Zhao

Research output: Contribution to journalArticle

Abstract

This study demonstrates a strong association of high urinary iodine with thyroid nodules and papillary thyroid cancer as well as aggressive cancer features, suggesting that high urinary iodine is a risk factor for thyroid cancer. The risk of high iodine intake for thyroid cancer has been suggested but not established. The objective of the study was to evaluate the relationship between urine iodine levels and thyroid nodule and thyroid cancer. We preoperatively tested fasting urine iodine in 154 thyroid nodule patients and correlated the results with pathological diagnoses and compared with 306 subjects as normal control. The median urine iodine (MUI) was 331.33 μg/L in patients with benign thyroid nodules versus 466.23 μg/L in patients with papillary thyroid cancer (PTC) (P = 0.003), both of which were in the excessive iodine state and higher than the MUI of 174.30 μg/L in the control group (P <0.001), which was in the sufficient iodine state. Excessive iodine state (MUI > 300 μg/L) was seen in 62.75 % of patients with benign thyroid nodules and 66.99 % of patients with PTC, both of which were significantly higher than the iodine excessive rate of 19.93 % in the control group (P <0.001). Moreover, MUI in patients with PTC with lymph node metastasis was significantly higher than that of PTC patients without lymph node metastasis (P <0.001). Urine iodine of thyroid cancer patients with stage III and IV disease was significantly higher than that of patients with stage I and II diseases (P <0.001). Multivariable analyses showed that, like sand calcification of thyroid nodule and TSH, urine iodine was an independent risk factor for PTC. These data demonstrate a significant association between high urinary iodine and benign and malignant thyroid nodules and PTC aggressiveness, supporting high urinary iodine as a risk factor for thyroid malignancy. Further studies are warranted to confirm these findings.

Original languageEnglish (US)
Pages (from-to)11375-11379
Number of pages5
JournalTumor Biology
Volume35
Issue number11
DOIs
StatePublished - 2014

Fingerprint

Thyroid Nodule
Iodine
Urine
Thyroid Neoplasms
Papillary Thyroid cancer
Lymph Nodes
Neoplasm Metastasis
Control Groups

Keywords

  • Papillary thyroid cancer
  • Thyroid nodule
  • Urine iodine

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)

Cite this

Strong association of high urinary iodine with thyroid nodule and papillary thyroid cancer. / Wang, Fang; Wang, Yangang; Wang, Luan; Wang, Xiuxiu; Sun, Chun; Xing, Michael Mingzhao; Zhao, Wenjuan.

In: Tumor Biology, Vol. 35, No. 11, 2014, p. 11375-11379.

Research output: Contribution to journalArticle

Wang, Fang ; Wang, Yangang ; Wang, Luan ; Wang, Xiuxiu ; Sun, Chun ; Xing, Michael Mingzhao ; Zhao, Wenjuan. / Strong association of high urinary iodine with thyroid nodule and papillary thyroid cancer. In: Tumor Biology. 2014 ; Vol. 35, No. 11. pp. 11375-11379.
@article{7028484fc40843b994bef7ff8cdc7058,
title = "Strong association of high urinary iodine with thyroid nodule and papillary thyroid cancer",
abstract = "This study demonstrates a strong association of high urinary iodine with thyroid nodules and papillary thyroid cancer as well as aggressive cancer features, suggesting that high urinary iodine is a risk factor for thyroid cancer. The risk of high iodine intake for thyroid cancer has been suggested but not established. The objective of the study was to evaluate the relationship between urine iodine levels and thyroid nodule and thyroid cancer. We preoperatively tested fasting urine iodine in 154 thyroid nodule patients and correlated the results with pathological diagnoses and compared with 306 subjects as normal control. The median urine iodine (MUI) was 331.33 μg/L in patients with benign thyroid nodules versus 466.23 μg/L in patients with papillary thyroid cancer (PTC) (P = 0.003), both of which were in the excessive iodine state and higher than the MUI of 174.30 μg/L in the control group (P <0.001), which was in the sufficient iodine state. Excessive iodine state (MUI > 300 μg/L) was seen in 62.75 {\%} of patients with benign thyroid nodules and 66.99 {\%} of patients with PTC, both of which were significantly higher than the iodine excessive rate of 19.93 {\%} in the control group (P <0.001). Moreover, MUI in patients with PTC with lymph node metastasis was significantly higher than that of PTC patients without lymph node metastasis (P <0.001). Urine iodine of thyroid cancer patients with stage III and IV disease was significantly higher than that of patients with stage I and II diseases (P <0.001). Multivariable analyses showed that, like sand calcification of thyroid nodule and TSH, urine iodine was an independent risk factor for PTC. These data demonstrate a significant association between high urinary iodine and benign and malignant thyroid nodules and PTC aggressiveness, supporting high urinary iodine as a risk factor for thyroid malignancy. Further studies are warranted to confirm these findings.",
keywords = "Papillary thyroid cancer, Thyroid nodule, Urine iodine",
author = "Fang Wang and Yangang Wang and Luan Wang and Xiuxiu Wang and Chun Sun and Xing, {Michael Mingzhao} and Wenjuan Zhao",
year = "2014",
doi = "10.1007/s13277-014-2397-8",
language = "English (US)",
volume = "35",
pages = "11375--11379",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "11",

}

TY - JOUR

T1 - Strong association of high urinary iodine with thyroid nodule and papillary thyroid cancer

AU - Wang, Fang

AU - Wang, Yangang

AU - Wang, Luan

AU - Wang, Xiuxiu

AU - Sun, Chun

AU - Xing, Michael Mingzhao

AU - Zhao, Wenjuan

PY - 2014

Y1 - 2014

N2 - This study demonstrates a strong association of high urinary iodine with thyroid nodules and papillary thyroid cancer as well as aggressive cancer features, suggesting that high urinary iodine is a risk factor for thyroid cancer. The risk of high iodine intake for thyroid cancer has been suggested but not established. The objective of the study was to evaluate the relationship between urine iodine levels and thyroid nodule and thyroid cancer. We preoperatively tested fasting urine iodine in 154 thyroid nodule patients and correlated the results with pathological diagnoses and compared with 306 subjects as normal control. The median urine iodine (MUI) was 331.33 μg/L in patients with benign thyroid nodules versus 466.23 μg/L in patients with papillary thyroid cancer (PTC) (P = 0.003), both of which were in the excessive iodine state and higher than the MUI of 174.30 μg/L in the control group (P <0.001), which was in the sufficient iodine state. Excessive iodine state (MUI > 300 μg/L) was seen in 62.75 % of patients with benign thyroid nodules and 66.99 % of patients with PTC, both of which were significantly higher than the iodine excessive rate of 19.93 % in the control group (P <0.001). Moreover, MUI in patients with PTC with lymph node metastasis was significantly higher than that of PTC patients without lymph node metastasis (P <0.001). Urine iodine of thyroid cancer patients with stage III and IV disease was significantly higher than that of patients with stage I and II diseases (P <0.001). Multivariable analyses showed that, like sand calcification of thyroid nodule and TSH, urine iodine was an independent risk factor for PTC. These data demonstrate a significant association between high urinary iodine and benign and malignant thyroid nodules and PTC aggressiveness, supporting high urinary iodine as a risk factor for thyroid malignancy. Further studies are warranted to confirm these findings.

AB - This study demonstrates a strong association of high urinary iodine with thyroid nodules and papillary thyroid cancer as well as aggressive cancer features, suggesting that high urinary iodine is a risk factor for thyroid cancer. The risk of high iodine intake for thyroid cancer has been suggested but not established. The objective of the study was to evaluate the relationship between urine iodine levels and thyroid nodule and thyroid cancer. We preoperatively tested fasting urine iodine in 154 thyroid nodule patients and correlated the results with pathological diagnoses and compared with 306 subjects as normal control. The median urine iodine (MUI) was 331.33 μg/L in patients with benign thyroid nodules versus 466.23 μg/L in patients with papillary thyroid cancer (PTC) (P = 0.003), both of which were in the excessive iodine state and higher than the MUI of 174.30 μg/L in the control group (P <0.001), which was in the sufficient iodine state. Excessive iodine state (MUI > 300 μg/L) was seen in 62.75 % of patients with benign thyroid nodules and 66.99 % of patients with PTC, both of which were significantly higher than the iodine excessive rate of 19.93 % in the control group (P <0.001). Moreover, MUI in patients with PTC with lymph node metastasis was significantly higher than that of PTC patients without lymph node metastasis (P <0.001). Urine iodine of thyroid cancer patients with stage III and IV disease was significantly higher than that of patients with stage I and II diseases (P <0.001). Multivariable analyses showed that, like sand calcification of thyroid nodule and TSH, urine iodine was an independent risk factor for PTC. These data demonstrate a significant association between high urinary iodine and benign and malignant thyroid nodules and PTC aggressiveness, supporting high urinary iodine as a risk factor for thyroid malignancy. Further studies are warranted to confirm these findings.

KW - Papillary thyroid cancer

KW - Thyroid nodule

KW - Urine iodine

UR - http://www.scopus.com/inward/record.url?scp=84927787429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927787429&partnerID=8YFLogxK

U2 - 10.1007/s13277-014-2397-8

DO - 10.1007/s13277-014-2397-8

M3 - Article

C2 - 25119588

AN - SCOPUS:84927787429

VL - 35

SP - 11375

EP - 11379

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 11

ER -